

## MATERIALS LICENSE

Amendment No. 23

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

"OFFICIAL RECORD COPY"

Licensee Government of the District of Columbia District of Columbia General Hospital 1. Department of Human Resources Health Services Administration 2. 19th Street and Massachusetts, Avenue, S.E. Washington, D.C. 20003		In accordance with application dated June 28, 1984, 3. License number 08-04289-06 is amended in its entirety to read as follows: 4. Expiration date April 30, 1990 5. Docket or Reference No. 030-01326	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.	
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 1.5 curies of each byproduct material authorized in Subitem 6.B.	
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.	
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.	
E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. 800 millicuries total for sources authorized in Subitem 6.E.	
F. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	F. Prepackaged kits	F. 5 millicuries of each byproduct material authorized in Subitem 6.F.	
8505300441 850509 REG1 LIC30 08-04289-06 PDR			
9. Authorized use			
A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations. B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations. C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations. D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.			

ML10

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

08-04239-06

Docket or Reference number

030-01326

Amendment No. 23

(9. continued)

- E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- F. In vitro studies.

**CONDITIONS**

10. Licensed material shall be used only at the licensee's facilities, Government of the District of Columbia, District of Columbia General Hospital, 19th and Massachusetts Avenue, S.E., Washington, D.C.
11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions, and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."
12. A. Licensed material shall be used by, or under the supervision of, individuals designated by the Radiation Safety Committee, Massih Kish, M.D., Chairman.
- B. The use of licensed material in or on humans shall be by a physician as defined in 10 CFR 35.3(b).
- C. Physicians designated to use licensed material in or on humans shall meet the training and experience criteria established in Appendix A of Regulatory Guide 10.8 (Revision 1), dated October 1980.
- D. The Radiation Protection Officer for the activities authorized by this license is Romey W. Keyes.
13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.
14. Sealed sources containing licensed material shall not be opened.
15. Patients containing Iodine 131 for the treatment of thyroid carcinoma shall remain hospitalized until the residual activity is 30 millicuries or less.
16. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:
- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
- B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
- C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

08-04289-06

Docket or Reference number

030-01326

Amendment No. 23

(Continued)

**CONDITIONS**

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated June 28, 1984 containing ALARA Program dated June 27, 1984; and letters dated March 5, 1985 and March 27, 1985 and Radiation Safety manual dated 1983. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Original Signed By:

John E. Glenn

By

Nuclear Materials Safety and  
Safeguards Branch, Region I  
King of Prussia, Pennsylvania 19406

Date

MAY 09 1985